Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RHU.0000000000001610 | DOI Listing |
Publication Analysis
Top Keywords
pembrolizumab-induced phenotypic
4
phenotypic switch
4
switch psoriatic
4
psoriatic arthritis
4
pembrolizumab-induced
1
switch
1
psoriatic
1
arthritis
1
Similar Publications
Pembrolizumab-Induced Phenotypic Switch in Psoriatic Arthritis.
J Clin Rheumatol
December 2021
From the Hospital for Special Surgery, New York, NY.
Increased Th17 activation and gut microbiota diversity are associated with pembrolizumab-triggered tuberculosis.
Cancer Immunol Immunother
December 2020
Department of Pulmonary Disease, PLA 905 Hospital, 9585 Humin Road, Shanghai, 200235, China.
Article Synopsis
- A hypersensitivity response similar to immune reconstitution inflammatory syndrome (IRIS) may contribute to tuberculosis cases induced by anti-PD-1 therapy, specifically through the activation of Th17 cells.
- Research involved analyzing T cell populations in lung cancer and tuberculosis, monitoring Th17 cell markers in a patient experiencing adverse effects from pembrolizumab, and examining gut microbiome changes.
- Findings indicated increased Th17 cells and CD38 expression in response to pembrolizumab, while gut microbiota analysis revealed greater diversity and a significant presence of Prevotella, linked to lung inflammation and Th17 activation.
Pembrolizumab (Keytruda).
Hum Vaccin Immunother
November 2016
a Department of Medicine , Queen Mary Hospital, Hong Kong.
The programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response. Ligation of PD1 with its ligands PDL1 and PDL2 results in transduction of negative signals to T-cells. PD1 expression is an important mechanism contributing to the exhausted effector T-cell phenotype.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!